Tirzepatide vs semaglutide, head-to-head data ends the debate.
In the SURMOUNT-5 trial (NEJM, 2025), adults with obesity but without type 2 diabetes lost 20.2% of their body weight on tirzepatide vs 13.7% on semaglutide over 72 weeks, a 47% larger weight reduction for tirzepatide. That's the cleanest direct comparison ever run between these two drugs. Below is the full breakdown of tirzepatide vs semaglutide: mechanism difference, dosing schedules, side effects, brand names (Mounjaro, Zepbound, Ozempic, Wegovy), cost, insurance coverage, dose-conversion chart for switching between them, and the honest answer on which one fits which patient.
Tirzepatide vs Semaglutide: Comparison Table
| Factor | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GLP-1 + GIP receptor agonist | GLP-1 receptor agonist (monoagonist) |
| Brand names | Mounjaro (T2D), Zepbound (obesity, OSA) | Ozempic (T2D), Wegovy (obesity), Rybelsus (oral T2D) |
| FDA approval year | 2022 (Mounjaro), 2023 (Zepbound) | 2017 (Ozempic), 2021 (Wegovy) |
| Weight loss (SURMOUNT-5, 72 wks, head-to-head) | 20.2% (50.3 lbs) | 13.7% (33 lbs) |
| A1C reduction (T2D) | ~2.4 percentage points | ~1.9 percentage points |
| Dosing | 2.5, 5, 7.5, 10, 12.5, 15 mg SC weekly | 0.25, 0.5, 1.0, 1.7, 2.4 mg SC weekly |
| Half-life | ~5 days | ~7 days |
| Top GI side effects | Nausea, constipation, diarrhea | Nausea, vomiting, diarrhea |
| Cardiovascular outcomes data | SURPASS-CVOT ongoing | SELECT trial, 20% MACE reduction (2023) |
| Cash cost (brand, monthly) | $1,000-1,300 | $900-1,300 |
| Lilly Direct / Novo cash option | Zepbound vials $349-549/month | Wegovy NovoCare $499/month |
| Best for | Maximum weight loss, A1C control | Cardiovascular protection, established CV outcomes data |
🔑 Key Takeaways
- Tirzepatide wins on weight loss. SURMOUNT-5 showed 20.2% vs 13.7%, a 47% relative advantage at 72 weeks.
- Semaglutide wins on cardiovascular evidence. The SELECT trial (2023) showed 20% reduction in major adverse cardiovascular events. Tirzepatide's SURPASS-CVOT trial hasn't read out yet.
- Different mechanisms, different brands. Tirzepatide = GLP-1 + GIP (Mounjaro/Zepbound). Semaglutide = GLP-1 only (Ozempic/Wegovy/Rybelsus).
- Side effect profiles are similar, intensity differs. GI events (nausea, constipation, diarrhea) dominate both at ~45-50% of users. Tirzepatide slightly more at 15 mg dose; semaglutide nausea profile slightly worse early.
- Cost is comparable at brand level; compounded options shift the math. Brand cash $1,000-1,300/month for either. Yucca compounded tirzepatide and semaglutide both at $146-258/month with telehealth.
SURMOUNT-5: The Head-to-Head Tirzepatide vs Semaglutide Trial
The single most important piece of evidence in the tirzepatide vs semaglutide debate is the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025 (Aronne et al., NEJM 2025; PMID 40353578). It's the first large-scale randomized trial directly comparing tirzepatide vs semaglutide in adults with obesity but without diabetes.
| SURMOUNT-5 design | Details |
|---|---|
| Type | Phase 3b, open-label, randomized, controlled |
| Population | Adults with obesity (BMI ≥30), no type 2 diabetes |
| Comparator doses | Tirzepatide 10 or 15 mg vs semaglutide 1.7 or 2.4 mg, both weekly SC |
| Primary endpoint | Percent change in body weight at 72 weeks |
| Funded by | Eli Lilly |
SURMOUNT-5 results at 72 weeks:
- Tirzepatide: 20.2% mean body-weight reduction (~50.3 lbs)
- Semaglutide: 13.7% mean body-weight reduction (~33 lbs)
- Absolute difference: 6.5 percentage points in favor of tirzepatide
- Relative difference: Tirzepatide produced 47% more weight loss
- Cardiovascular post-hoc: A 2025 post-hoc analysis (Mamas et al., Eur Heart J Open 2025) showed tirzepatide produced larger 10-year cardiovascular disease risk reduction than semaglutide.
Critical caveat: SURMOUNT-5 was an open-label trial sponsored by Eli Lilly (the maker of tirzepatide). The result is consistent with smaller prior comparisons, but bias-adjusted confirmation would benefit from an independent head-to-head, which hasn't happened as of mid-2026.
How Tirzepatide and Semaglutide Work (Mechanism Difference)
Both drugs are once-weekly subcutaneous injections that act on the same broad pathway, the body's incretin hormone system. The difference is which receptors they hit.
| Receptor activation | Tirzepatide | Semaglutide |
|---|---|---|
| GLP-1 receptor | Yes, agonist | Yes, agonist |
| GIP receptor | Yes, agonist (the "+1" advantage) | No |
| Glucagon receptor | No | No |
GLP-1 (glucagon-like peptide-1) activation suppresses appetite, slows gastric emptying, and improves insulin secretion. GIP (glucose-dependent insulinotropic polypeptide) activation adds nutrient-stimulated insulin release plus an apparent benefit for glucose handling and weight loss that GLP-1 alone doesn't deliver. The dual GLP-1 + GIP mechanism is why tirzepatide outperforms semaglutide head-to-head on both A1C reduction and weight loss.
Tirzepatide vs Semaglutide: Brand Names and Indications
| Brand | Active drug | FDA indication | Year |
|---|---|---|---|
| Mounjaro | Tirzepatide | Type 2 diabetes | 2022 |
| Zepbound | Tirzepatide | Chronic weight management + obstructive sleep apnea in obesity (2024) | 2023 |
| Ozempic | Semaglutide | Type 2 diabetes | 2017 |
| Wegovy | Semaglutide | Chronic weight management; cardiovascular risk reduction (2024) | 2021 |
| Rybelsus | Semaglutide (oral) | Type 2 diabetes, oral tablet | 2019 |
Practical implication: prescribers usually pick by indication, not chemistry. Type 2 diabetes patients get Mounjaro or Ozempic. Obesity patients get Zepbound or Wegovy. Off-label use crosses these lines often. See our Mounjaro vs Ozempic comparison and Zepbound vs Wegovy comparison for brand-specific breakdowns.
Tirzepatide vs Semaglutide: Side Effects Compared
The side effect profiles are similar in pattern, slightly different in intensity. Most events are gastrointestinal and concentrated in the first 2-4 weeks of each new dose level.
| Side effect | Tirzepatide rate | Semaglutide rate |
|---|---|---|
| Nausea | ~28-31% | ~33-44% |
| Diarrhea | ~17-23% | ~17-30% |
| Vomiting | ~10-15% | ~18-24% |
| Constipation | ~11-17% | ~12-24% |
| Injection site reactions | ~3-5% | ~3-7% |
| Hair loss / shedding | ~5-6% | ~3-5% |
| Pancreatitis (serious, rare) | ~0.1-0.4% | ~0.1-0.4% |
| Thyroid C-cell tumor warning | Black box (early toxicology) | Black box (early toxicology) |
| NAION (vision loss, 2025 label) | Labeled risk | Labeled risk |
| Gastroparesis lawsuits (MDL) | Active litigation | Active litigation |
Detailed comparisons in our tirzepatide side effects guide and semaglutide side effects guide. Both drugs carry the same black box warning for thyroid C-cell tumors and the same recent NAION (sudden vision loss) label addition from 2025.
Tirzepatide vs Semaglutide: Dosing Schedule
Both drugs follow a slow titration schedule to minimize GI side effects. The starting doses are small and you escalate every 4 weeks.
| Week | Tirzepatide (Mounjaro/Zepbound) | Semaglutide (Wegovy) |
|---|---|---|
| Weeks 1-4 | 2.5 mg weekly | 0.25 mg weekly |
| Weeks 5-8 | 5 mg weekly | 0.5 mg weekly |
| Weeks 9-12 | 7.5 mg weekly | 1.0 mg weekly |
| Weeks 13-16 | 10 mg weekly | 1.7 mg weekly |
| Weeks 17-20 | 12.5 mg weekly | 2.4 mg weekly (maintenance) |
| Weeks 21+ | 15 mg weekly (max maintenance) | 2.4 mg weekly (maintenance) |
Tirzepatide vs Semaglutide: Dose Conversion Chart
For people switching from semaglutide to tirzepatide or vice versa, there's no official 1:1 conversion. Doses target similar potency endpoints but on completely different mg scales. Most clinicians use this approximate equivalence based on weight-loss response in SURMOUNT-5 and SURPASS-2:
| Semaglutide dose | Approx tirzepatide equivalent |
|---|---|
| 0.25 mg | 2.5 mg |
| 0.5 mg | 5 mg |
| 1.0 mg | 7.5 mg |
| 1.7 mg | 10 mg |
| 2.4 mg (max Wegovy) | 12.5-15 mg (titrate based on tolerance) |
These are approximations only, not pharmacologic equivalence. Always switch with prescriber supervision; see our switching from semaglutide to tirzepatide guide for the full protocol including wash-out periods and GI side-effect-management.
Tirzepatide vs Semaglutide: Cost Comparison
| Source / route | Tirzepatide cost | Semaglutide cost |
|---|---|---|
| Brand cash (no insurance) | $1,000-1,300/month | $900-1,300/month |
| Manufacturer cash program | Lilly Direct Zepbound vials: $349-549/month | Novo NovoCare Wegovy: $499/month |
| Commercial insurance copay | $25-200/month with prior auth | $25-200/month with prior auth |
| Medicare | Often covers Mounjaro for T2D; Zepbound rarely covered | Often covers Ozempic for T2D; Wegovy coverage variable |
| Compounded via telehealth (Yucca) | $146-258/month | $146-258/month |
| Specialty compounding pharmacy (Rx) | $150-400/month | $150-400/month |
The most cost-effective path for most uninsured or underinsured patients in 2026: telehealth-based compounded tirzepatide or compounded semaglutide. Same molecule as brand, doctor-supervised prescription, third-party tested. The trade-off vs brand is the gray regulatory zone around compounding restrictions; see our compounded tirzepatide and compounded semaglutide guides.
Tirzepatide vs Semaglutide: Cardiovascular and Off-Label Benefits
| Benefit category | Tirzepatide | Semaglutide |
|---|---|---|
| Cardiovascular event reduction | Suggested in post-hoc; SURPASS-CVOT not yet read out | Established (SELECT trial 2023, 20% MACE reduction) |
| Obstructive sleep apnea | FDA approved (Zepbound, 2024) | Not FDA approved for OSA |
| Heart failure with preserved ejection fraction | SUMMIT trial positive (2024) | STEP-HFpEF trial positive |
| Chronic kidney disease (T2D) | Likely benefit (extrapolated) | FLOW trial 2024 confirmed renal benefit |
| Non-alcoholic steatohepatitis (MASH) | SYNERGY-NASH positive (2024) | ESSENCE trial positive (2024) |
| Alcohol use disorder | Emerging evidence (trials ongoing) | Emerging evidence (trials ongoing) |
| Food noise reduction | Universal patient report | Universal patient report |
Plain English: semaglutide has more established cardiovascular outcomes data (SELECT was the landmark trial), while tirzepatide is rapidly catching up and has the only FDA-approved obstructive sleep apnea indication in this drug class. For broader off-label benefits including brain effects and addiction-adjacent uses, see our tirzepatide off-label uses guide.
Switching Between Tirzepatide and Semaglutide
Switching is common and generally well-tolerated when done correctly. Common scenarios:
- Semaglutide → tirzepatide: Most common direction (patients seeking more weight loss). Stop semaglutide, wait 1 full week, start tirzepatide at the equivalent dose level using the conversion chart above. Most patients tolerate the switch without re-titrating from 2.5 mg.
- Tirzepatide → semaglutide: Less common, usually for cost, supply, or cardiovascular-outcome reasons. Stop tirzepatide, wait 1 full week, start semaglutide at the equivalent dose level. Some patients see GI side effects re-emerge because semaglutide's nausea profile is slightly stronger.
- Switching for fertility planning: Both drugs are contraindicated in pregnancy. Discontinue at least 2 months before attempting conception (both half-lives ~5-7 days, full clearance takes 4-5 weeks).
What Real Users Report (Reddit, Patient Forums)
The Reddit consensus on r/Mounjaro, r/Zepbound, r/Ozempic, and r/Wegovy in 2026 aligns closely with the SURMOUNT-5 data: tirzepatide users report more dramatic weight loss and less hunger; semaglutide users report similar appetite suppression at lower mg doses but with sometimes harsher nausea. Other consistent patterns:
- Sleep changes: Both drugs frequently improve sleep quality, especially for users with sleep apnea or weight-related sleep disruption.
- Food noise: Universally reported reduction within the first 1-3 days for both drugs.
- Alcohol tolerance drop: Reported widely on both. Many users naturally reduce alcohol intake.
- Tirzepatide is harder to find: Compounded restrictions tightened in late 2024 affecting both, but tirzepatide's brand price stayed higher longer.
- Switching satisfaction: Most switchers from semaglutide to tirzepatide report no regret. Switchers from tirzepatide to semaglutide (usually cost-driven) report some loss of effect.
Drug Interactions: Tirzepatide vs Semaglutide
Both drugs share the same primary interaction concern: delayed gastric emptying that can affect absorption of other oral medications.
- Oral contraceptives: Reduced absorption is theoretical with both drugs. Use a non-oral contraceptive method or backup method for 4 weeks after starting and 4 weeks after each dose increase.
- Insulin and sulfonylureas: Increased hypoglycemia risk. Dose adjustment required.
- Levothyroxine (Synthroid): Delayed absorption. Take 60 minutes before any food or injection.
- Warfarin: Monitor INR more closely; absorption can shift.
- Other GLP-1 drugs: Do NOT combine tirzepatide and semaglutide. Same receptor pathway means stacking adds side effects without adding benefits.
Who Should Pick Tirzepatide vs Semaglutide
Pick tirzepatide if you:
- Want the largest possible weight loss (SURMOUNT-5 confirmed)
- Have type 2 diabetes needing aggressive A1C reduction
- Have moderate-to-severe obstructive sleep apnea in obesity (Zepbound is FDA-approved here)
- Failed semaglutide due to insufficient weight loss
- Are willing to escalate to 12.5-15 mg over 4-5 months
Pick semaglutide if you:
- Have established cardiovascular disease and want the SELECT-trial CV benefit
- Need an oral option (Rybelsus tablet for type 2 diabetes)
- Have insurance that covers Ozempic or Wegovy but not Mounjaro or Zepbound
- Prefer the longer pharmacology safety track record (semaglutide approved 2017 vs tirzepatide 2022)
- Want the lower NovoCare cash-pay option for Wegovy ($499/month)
How to Get Tirzepatide or Semaglutide
- Brand prescription via doctor or telehealth: Standard path. Insurance may cover with prior authorization for qualifying diagnosis. Lilly Direct ($349-549 Zepbound vials) and Novo NovoCare ($499 Wegovy) offer manufacturer cash options.
- Compounded via reputable telehealth clinic: Yucca Health and similar providers offer doctor-supervised compounded tirzepatide and compounded semaglutide at $146-258/month. Doctor consultation included.
- 503A compounding pharmacy with your own Rx: Bring a prescription from any prescriber. Pricing varies by pharmacy.
Frequently Asked Questions
The Bottom Line: Tirzepatide vs Semaglutide
If your primary goal is weight loss, tirzepatide is the better choice based on the strongest direct evidence we have (SURMOUNT-5, NEJM 2025). If you have established cardiovascular disease and want the most evidence-backed cardiovascular protection, semaglutide remains the better choice based on the SELECT trial. For most users without strong CV indications, tirzepatide is the modern default, and the price difference between the two has narrowed enough that cost is rarely the deciding factor.
References
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. DOI: 10.1056/NEJMoa2416394 (PMID: 40353578)
- Mamas MA, Bays H, Li R, et al. Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial. Eur Heart J Open. 2025;5(5):oeaf117. PMID: 40980721
- FDA-approved prescribing information for Mounjaro, Zepbound, Ozempic, Wegovy, and Rybelsus.
- SELECT trial: semaglutide cardiovascular outcomes in obesity (Lincoff et al., NEJM 2023).
- SURMOUNT-1 and SURPASS-2 trials (tirzepatide weight loss + head-to-head A1C trials).
Meal planning: Both semaglutide and tirzepatide users follow similar dietary patterns. See our Ozempic meal plan for the 7-day menu, protein targets, and foods to avoid on either drug.
Medical disclaimer: This article is for educational and informational purposes only and is not medical advice. Tirzepatide and semaglutide are both prescription medications. The comparisons in this article are based on published clinical trial data and US regulatory status as of May 2026. Talk to a qualified prescriber about which option fits your specific medical history, comorbidities, and goals before starting, switching, or stopping either medication.